We are #recruiting patients for our #phase2 clinical study for the treatment of #incontinence! www.muvon-studie.ch Check out this website for more information on the study and how to sign up and follow MUVON for more information on the trial! A big thank you to the team from admedicum for the great collaboration to design the website and for supporting us in our recruitment! We also want to thank everyone at Wyss Zurich and the Department of Urology at the Universitätsspital Zürich for their efforts so far! And of course the entire MUVON team that is working tirelessly to make our regenerative cell therapy a reality for patients in need! #muvon #regaincontrol #clinicaltrials #celltherapy #regenerativemedicine #milestone #patientengagement #team #thankyou
MUVON Therapeutics AG
Biotechnologieforschung
Regain control with personalized muscle regeneration
Info
MUVON Therapeutics is a clinical stage Life Science spin-off from the University of Zurich developing a therapeutic platform for the regeneration of skeletal muscle tissue based on autologous cells, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles. Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.
- Website
-
https://www.muvon-therapeutics.com/
Externer Link zu MUVON Therapeutics AG
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Zurich
- Art
- Privatunternehmen
- Gegründet
- 2020
Orte
-
Primär
Wegbeschreibung
Zurich, CH
Beschäftigte von MUVON Therapeutics AG
Updates
-
Excited to announce that Beatrix Rauch Schmid, one of our esteemed team members at MUVON, has been featured in the prestigious Globe Magazine of ETH Zurich! In this insightful article, ETH alumni share their valuable perspectives on innovation and the key factors driving success in today’s fast-paced world. Their dedication and expertise are a testament to the high standards and innovative spirit in Switzerland, that we strive to uphold at MUVON. https://lnkd.in/dx9rZKVG
🌐 It was a great pleasure to give an interview for this inspiring article about how our fellow ETH Zürich alumni are driving innovation worldwide and boosting Switzerland’s innovation ecosystem. Check it out: https://lnkd.in/ds5-BcHi It is a great honor to be among these luminaries like Dominik Blunschy, Tilla Theus, Luca Di Tizio, Bigna Salzmann, Denniz Dönmez, PhD, Manuel Suter, Myke Näf, Oriana Kraft, Garif Yalak, Dr. sc. ETH, MBA HSG, Lukas Ambühl, Rea Sodero (Schegg). Let’s celebrate great achievements and the impact we’re making with all the other brilliant innovators among us! 💡 🌟 In my daily role at MUVON Therapeutics, I’m passionate about creating solutions that push boundaries and improve patients lives. 🚀 #ETHZurich #AlumniPride #StartupLife #Wysszurich #healthcareinnovation #Innovation #MedicalAdvancements #UZHinnovation
-
-
We at MUVON are proud supporters of the #urgetoact campaign @EAU and International Continence Society (ICS) and especially so during the #worldincontineneceweek , supporting the efforts to destigmatise #incontinence together with our partners from the World Federation of Incontinence and Pelvic Problems - WFIPP ! Glad to be at the frontline, helping patients in need by means of regenerative medicine! #regaincontrol #wfipp #sui
Incontinence adds an economic burden in addition to a physical one. The Urge to Act report released in November 2023 found that incontinence costs European society over €60 billion per year. If no action is taken, continence care costs are expected to rise to to €86 billion by 2030. #WorldContinenceWeek
-
-
Participate in the TOP 100 Public Voting and support your favorite startup! Until July 21st, 2024, all LinkedIn users have one vote each in the public competition to choose the 10 most innovative Swiss startups: https://lnkd.in/eem8TVvJ The winners will be celebrated on stage at the award night on September 4, 2024. We will honor one winner for each of the 10 sectors: Biotech, Cleantech, Engineering, Fintech, Foodtech, ICT, Medtech, Proptech, Robotics, and Security. Here’s how you can vote for your TOP 100 Swiss startup: all Swiss startups that are listed on startup.ch and incorporated on or after January 1, 2019, are eligible for your vote. Voting is as easy as 1-2-3: - Visit www.startup.ch to see all eligible startups. - Select your favorite startup and click the golden “Vote now” button on the startup’s profile. - Log in with your LinkedIn profile to cast your vote. Each user is entitled to one vote. All votes must be submitted by midnight on July 21, 2024. Thanks for your support in choosing Switzerland's most innovative startups! #TOP100SSU #SwissStartups
TOP 100 Swiss Startup Award 2024: The TOP 100 Public Voting 2024 is open!
top100startups.swiss
-
🚀 Excited to share our latest article at @founded.ch Discover how our innovative approach is transforming lives. Utilizing tissue engineering, MUVON regenerates muscles with patients' own cells, offering a game-changing solution. Read the full interview here: https://lnkd.in/dpWwjsrW #HealthcareInnovation #TissueEngineering #BladderIncontinence #StartupSuccess #MUVON #MedicalBreakthroughs #regaincontrol #wysszurich #uzhinnovation
MUVON: die revolutionäre Therapie gegen Blaseninkontinenz - FOUNDED.
https://founded.ch
-
🌟 Exciting News! 🌟 We are thrilled to share that MUVON Therapeutics has been featured by #Nature as one of the leading companies pioneering innovative treatments for stress urinary incontinence. This recognition underscores the immense potential and crucial advancements in women's health and beyond that we are committed to achieving. Our dedication to improving quality of life through cutting-edge personalized therapies is at the heart of everything we do. #WomensHealth #Innovation #Healthcare #StressUrinaryIncontinence #Nature #MedicalAdvancements #Biotechnology #UZHinnovation https://lnkd.in/dyiYbQ_r
Femtechs take on women’s health - Nature Biotechnology
nature.com
-
🌍💡 At MUVON Therapeutics, we are proud to be at the forefront of a global movement dedicated to improving women's health. Despite women constituting roughly 50% of the world's population, only 1% of research and development funding is directed toward non-cancer-related women’s health issues. This disparity is unacceptable and highlights a critical need for change. Investing in women's health is not just a moral imperative; it is also a significant opportunity for growth and innovation. Addressing diseases that affect millions of women worldwide can lead to groundbreaking discoveries and improved health outcomes. Together, we can create a future NOW by driving growth and understanding for diseases that have long been overlooked. If you want to support our impactful journey, please reach out to join our new fundraising round, enabling our pivotal clinical trial. #WomensHealth #HealthcareInnovation #InvestInWomen #GlobalHealth #RaisingAwareness #HealthcareInvestment #Stressurinaryincontinence #regenerativemedicine #regaincontrol https://lnkd.in/edShebXp
Closing the gender health gap is a $1 trillion opportunity
nature.com
-
Last year MUVON Therapeutics AG reached top3 biotech start-up in Switzerland both on investor and public voting! Now, it's again YOUR turn to weigh in! 📣 Cast your vote for MUVON: the biotech start up that is helping people regain control of their lives by making personalized medicine a reality. Your support could help propel us to even greater heights! One click time! #Venturelab! #top100ssu #MUVON #regaincontrol https://lnkd.in/eD4fvDZg
Participate in the TOP 100 Public Voting and support your favorite startup! Until July 21st, 2024, all LinkedIn users have one vote each in the public competition to choose the 10 most innovative Swiss startups: https://lnkd.in/eem8TVvJ The winners will be celebrated on stage at the award night on September 4, 2024. We will honor one winner for each of the 10 sectors: Biotech, Cleantech, Engineering, Fintech, Foodtech, ICT, Medtech, Proptech, Robotics, and Security. Here’s how you can vote for your TOP 100 Swiss startup: all Swiss startups that are listed on startup.ch and incorporated on or after January 1, 2019, are eligible for your vote. Voting is as easy as 1-2-3: - Visit www.startup.ch to see all eligible startups. - Select your favorite startup and click the golden “Vote now” button on the startup’s profile. - Log in with your LinkedIn profile to cast your vote. Each user is entitled to one vote. All votes must be submitted by midnight on July 21, 2024. Thanks for your support in choosing Switzerland's most innovative startups! #TOP100SSU #SwissStartups
TOP 100 Swiss Startup Award 2024: The TOP 100 Public Voting 2024 is open!
top100startups.swiss
-
🌟 Thrilled to share this insightful read on stress incontinence in our latest #ScienceCommunications article! Shedding light on this prevalent issue and discussing potential solutions. Let's break down barriers and promote understanding in healthcare together. Check it out! (German translation in the comments) #ScienceCommunication #patientrecruitment #Healthcare #StressUrinaryIncontinence #SciComm #Wysszurich 🚀📝 https://lnkd.in/dV95cTaE
Why we need muscle cell regeneration technologies for stress incontinence
science-communications.ch
-
The #Swiss Biotech Days 2024 kick off in two weeks. On Monday 22 April, Deana Mohr-Haralampieva will be presenting an update on the development of our novel tissue engineering therapy for the treatment of stress urinary incontinence. We are looking forward to an exciting event full of inspiring discussions and exchanges! Deana Mohr-Haralampieva Steve Kappenthuler #muvon #regaincontrol #wysszurich #regenerativemedicine #congress #inspiration #networking #startup #bladdersmatter #dreamingbig
-